119 related articles for article (PubMed ID: 16633998)
1. [Diabetic nephropathy: oral anti-diabetic agents or insulin?].
Gigante E
G Ital Nefrol; 2006; 23 Suppl 34():S64-7. PubMed ID: 16633998
[TBL] [Abstract][Full Text] [Related]
2. Insulin therapy in renal disease.
Iglesias P; Díez JJ
Diabetes Obes Metab; 2008 Sep; 10(10):811-23. PubMed ID: 18248491
[TBL] [Abstract][Full Text] [Related]
3. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease.
Snyder RW; Berns JS
Semin Dial; 2004; 17(5):365-70. PubMed ID: 15461745
[TBL] [Abstract][Full Text] [Related]
4. Effects of KIOM-79 on hyperglycemia and diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats.
Kim CS; Sohn EJ; Kim YS; Jung DH; Jang DS; Lee YM; Kim DH; Kim JS
J Ethnopharmacol; 2007 May; 111(2):240-7. PubMed ID: 17194556
[TBL] [Abstract][Full Text] [Related]
5. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
[TBL] [Abstract][Full Text] [Related]
6. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
Raskin P
Diabetes Metab Res Rev; 2008; 24(1):3-13. PubMed ID: 17968971
[TBL] [Abstract][Full Text] [Related]
7. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
8. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
[TBL] [Abstract][Full Text] [Related]
9. [Metformin-associated lactic acidosis].
Orban JC; Ghaddab A; Chatti O; Ichai C
Ann Fr Anesth Reanim; 2006 Oct; 25(10):1046-52. PubMed ID: 17005358
[TBL] [Abstract][Full Text] [Related]
10. When oral agents fail: optimizing insulin therapy in the older adult.
Meece J
Consult Pharm; 2009 Jun; 24 Suppl B():11-7. PubMed ID: 19555131
[TBL] [Abstract][Full Text] [Related]
11. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
Massi-Benedetti M; Orsini-Federici M
Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
[TBL] [Abstract][Full Text] [Related]
12. [Insulin requirement in patients with type 1 diabetes with reduced renal function: human insulin versus analogue insulin].
Hasslacher C; Vogt C; Raupp D; Dreyhaupt J
Dtsch Med Wochenschr; 2007 Nov; 132(47):2500-4. PubMed ID: 18027324
[TBL] [Abstract][Full Text] [Related]
13. [Insulin analogues: place of detemir (levemir)].
Dorchy H; Sternon J
Rev Med Brux; 2006; 27(2):89-94. PubMed ID: 16736846
[TBL] [Abstract][Full Text] [Related]
14. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
Monami M; Marchionni N; Mannucci E
Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
[TBL] [Abstract][Full Text] [Related]
15. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
16. [Diabetic nephropathy and prevention of diabetic nephropathy caused chronic renal insufficiency].
Jakić M; Jakić M; Zibar L; Mihaljević D; Stipanić S; Teskera T
Lijec Vjesn; 2009; 131(7-8):218-25. PubMed ID: 19769285
[TBL] [Abstract][Full Text] [Related]
17. Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.
Panchapakesan U; Chen XM; Pollock CA
Nat Clin Pract Nephrol; 2005 Nov; 1(1):33-43. PubMed ID: 16932362
[TBL] [Abstract][Full Text] [Related]
18. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis.
Monami M; Lamanna C; Marchionni N; Mannucci E
Exp Clin Endocrinol Diabetes; 2009 May; 117(5):220-2. PubMed ID: 19301231
[TBL] [Abstract][Full Text] [Related]
19. Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control.
Robertson C
Diabetes Educ; 2006; 32(3):423-32. PubMed ID: 16772658
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of advanced glycation end products (AGEs): an implicit goal in clinical medicine for the treatment of diabetic nephropathy?
Miyata T; Dan T
Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S25-9. PubMed ID: 18954918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
